Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rapamune Labeling Will Reflect “Excess Rate Of Death” In Liver Transplants

Executive Summary

Labeling for Wyeth's immunosuppressant drug Rapamune will be updated to reflect "an excess rate of death and graft loss" when used after liver transplant

You may also be interested in...



Wyeth Rapamune Boxed Warning On Lung Transplants Added To Labeling

Wyeth has added a boxed warning to Rapamune labeling to reflect an increased incidence of bronchial anastomotic dehiscence in de novo lung transplant patients administered the immunosuppressant

Wyeth Rapamune Boxed Warning On Lung Transplants Added To Labeling

Wyeth has added a boxed warning to Rapamune labeling to reflect an increased incidence of bronchial anastomotic dehiscence in de novo lung transplant patients administered the immunosuppressant

Wyeth Rapamune May Need New U.S. Trial For Cyclosporine-Free Regimen

Wyeth's proposed Rapamune cyclosporine-free regimen may need another U.S. study before approval, FDA's Antiviral Drugs Immunosuppressive Subcommittee Advisory Committee indicated at its Jan. 24 meeting

Related Content

UsernamePublicRestriction

Register

PS039754

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel